Gilead buys into CAR-T with $11.9bn deal for Kite – PharmaTimes
|
Gilead buys into CAR–T with $11.9bn deal for Kite
PharmaTimes Gilead Sciences is buying Kite Pharma in a deal worth $11.9 billion, securing itself access to the latter's experimental CAR-T therapy axicabtagene ciloleucel and wider cancer pipeline. … involves drawing T cells from a patient's blood and … So Long To KITE; JUNO, CLLS, MBIO, BLCM Are Sympathy Plays; PGNX Catches Eye |
